Biogen taps City Therapeutics in RNAi deal worth up to $1B

News

May 27

Written By Rachel Swansburg

News

Rachel Swansburg

City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies